Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mineralys Therapeutics, Inc. ( (MLYS) ) has issued an update.
On September 2, 2025, Mineralys Therapeutics, Inc. announced the suspension and termination of its prospectus supplement related to its common stock offering, originally dated April 11, 2024. The company will not proceed with any stock sales under the existing Sales Agreement with BofA Securities, Inc. and Evercore Group L.L.C. until a new prospectus supplement is filed, although the Sales Agreement itself remains active.
The most recent analyst rating on (MLYS) stock is a Buy with a $43.00 price target. To see the full list of analyst forecasts on Mineralys Therapeutics, Inc. stock, see the MLYS Stock Forecast page.
Spark’s Take on MLYS Stock
According to Spark, TipRanks’ AI Analyst, MLYS is a Neutral.
Mineralys Therapeutics shows promise with positive clinical trial results and a strong cash position, but faces challenges with continuous losses and negative cash flows. Technical analysis suggests short-term momentum, while valuation remains a concern due to lack of revenue. The earnings call highlighted upcoming milestones that could enhance future prospects.
To see Spark’s full report on MLYS stock, click here.
More about Mineralys Therapeutics, Inc.
Average Trading Volume: 826,493
Technical Sentiment Signal: Buy
Current Market Cap: $1.03B
Learn more about MLYS stock on TipRanks’ Stock Analysis page.